A first Phase I pilot veterinary trial exploiting the safety and the anti-tumor potential of a xenogeneic DNA vaccine coding for the human tyrosinase in dogs affected by advanced malignant melanoma was conducted in 2003 by Bergman and collaborators [138]. Here, TYR is linked to melanoma.